The objective of this study is to evaluate the effectiveness and safety of XIENCE Skypoint stents in comparison to other drug-eluting stents (DES) in real-world practice.
Study Type
OBSERVATIONAL
Enrollment
2,000
Percutaneous coronary intervention with Xience-Skypoint™ stent
Asan Medical Hospital
Seoul, South Korea
RECRUITINGthe composite event rate of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post procedure. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.
Time frame: 12 months
the event rate of all cause death
Time frame: 5 years
the event rate of cardiac death
Time frame: 5 years
the event rate of nonfatal myocardial infarction
Time frame: 5 years
the composite event rate of death, or nonfatal myocardial infarction (MI)
Time frame: 5 years
the composite event rate of cardiac death, or nonfatal myocardial infarction (MI)
Time frame: 5 years
the event rate of Target- Vessel Revascularization (TVR)
Time frame: 5 years
the event rate of Target- lesion Revascularization (TLR)
Time frame: 5 years
the event rate of stent thrombosis
according to an Academic Research Consortium (ARC) criteria
Time frame: 5 years
the event rate of stroke
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 5 years
the event rate of Procedural success
(defined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
Time frame: 7 days